Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant protective antigen anthrax vaccine
- Development stage
- Unknown
- Lead developer
- DynPort Vaccine Company
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant protective antigen (rPA) anthrax vaccine is a protein subunit vaccine developed by DynPort Vaccine Company (DVC), a GDIT company, for the prevention of anthrax. The vaccine consists of a purified recombinant version of the Protective Antigen (PA) protein of *Bacillus anthracis*, produced in an *E. coli* expression system. PA is the key component of the anthrax toxin; the vaccine works by eliciting neutralizing antibodies that prevent PA from binding to cellular receptors, thereby blocking the entry of lethal factor (LF) and edema factor (EF) into host cells. This recombinant approach aims to provide a more consistent and better-characterized alternative to the older, filtrate-based Anthrax Vaccine Adsorbed (AVA). The vaccine is typically formulated with an aluminum-based adjuvant to enhance immunogenicity.
- Other names
- rPA anthrax vaccineE. coli-derived recombinant protective antigenrPA102rPA-102rPA 102
02
Targets
PA (Influenza polymerase acidic protein)
Beyond the preview
Go deeper on recombinant protective antigen anthrax vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant protective antigen anthrax vaccine.